Hervé Chneiweiss
Has grant
Research director
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Inovative therapeutic strategies against glioblastomas : combining disruption of stemness and metabolism
Open Date: 2012-12-27
Close Date: 2015-12-27
Articles (10)
Year:
2026
Year:
2026
Year:
2026
Year:
2025
Year:
2025
Year:
2024
Year:
2023
Glioblastomas (GBs) are incurable brain tumors. The persistence of aggressive stem-like tumor cells after cytotoxic treatments compromises therapeutic efficacy, leading to GBM recurrence. Forcing the GBM cells to irreversibly abandon their aggressive stem-like phenotype may offer an alternative to conventional cytotoxic treatments. Here, we show that the RNA binding protein CELF2 is strongly expressed in mitotic and OLIG2-positive GBM cells, while it is downregulated in differentiated and non-mitotic cells by miR-199a-3p, exemplifying GBM intra-tumor heterogeneity. Using patient-derived cells and human GBM samples, we demonstrate that CELF2 plays a key role in maintaining the proliferative/OLIG2 cell phenotype with clonal and tumorigenic properties. Indeed, we show that CELF2 deficiency in patient-derived GSCs drastically reduced tumor growth in the brains of nude mice. We further show that CELF2 promotes TRIM28 and G9a expression, which drive a H3K9me3 epigenetic profile responsible for the silencing of the SOX3 gene. Thus, CELF2, which is positively correlated with OLIG2 and Ki67 expression in human GBM samples, is inversely correlated with SOX3 and miR-199a-3p. Accordingly, the invalidation of SOX3 in CELF2-deficient patient-derived cells rescued proliferation and OLIG2 expression. Finally, patients expressing SOX3 above the median level of expression tend to have a longer life expectancy. CELF2 is therefore a crucial target for the malignant potential of GBM and warrants attention when developing novel anticancer strategies.
Year:
2023
Year:
2023
Year:
2023
Collaborators (13)
Aviad Raz
Ben-Gurion University of the Negev
Michel Salzet
Distuguish Professor (PRCE2)
Ministère de l'Éducation Nationale
ELIAS EL-HABR
Full Professor
Sorbonne Université
Ruth Horn
University of Oxford
Thierry Galli
Directeur
INSERM
Marie-Pierre Junier
Research Director INSERM
INSERM
Eric Chevet
head
INSERM
James Buchanan
Senior Lecturer
Queen Mary University of London
ANNIE LADOUX
INSERM
Angus Clarke
Cardiff University
Jean-Philippe Hugnot
Professor
University of Montpellier
Thierry Virolle
INSERM
Catherine Bourgain
Research Director
INSERM
Make your next move.
Prepare your application
Review drafts before you send them.